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Metformin Blunts Muscle Hypertrophy in Response to Progressive Resistance 
Exercise Training in Older Adults: A Randomized, Double‐Blind, 
Placebo‐Controlled, Multicenter Trial: The MASTERS Trial 
Abstract 
Progressive resistance exercise training (PRT) is the most effective known intervention for combating 
aging skeletal muscle atrophy. However, the hypertrophic response to PRT is variable, and this may be 
due to muscle inflammation susceptibility. Metformin reduces inflammation, so we hypothesized that 
metformin would augment the muscle response to PRT in healthy women and men aged 65 and older. In 
a randomized, double-blind trial, participants received 1,700 mg/day metformin (N = 46) or placebo (N = 
48) throughout the study, and all subjects performed 14 weeks of supervised PRT. Although responses to 
PRT varied, placebo gained more lean body mass (p = .003) and thigh muscle mass (p < .001) than 
metformin. CT scan showed that increases in thigh muscle area (p = .005) and density (p = .020) were 
greater in placebo versus metformin. There was a trend for blunted strength gains in metformin that did 
not reach statistical significance. Analyses of vastus lateralis muscle biopsies showed that metformin did 
not affect fiber hypertrophy, or increases in satellite cell or macrophage abundance with PRT. However, 
placebo had decreased type I fiber percentage while metformin did not (p = .007). Metformin led to an 
increase in AMPK signaling, and a trend for blunted increases in mTORC1 signaling in response to PRT. 
These results underscore the benefits of PRT in older adults, but metformin negatively impacts the 
hypertrophic response to resistance training in healthy older individuals. ClinicalTrials.gov Identifier: 
NCT02308228. 
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Abstract
Progressive resistance exercise training (PRT) is the most effective known interven‐
tion for combating aging skeletal muscle atrophy. However, the hypertrophic re‐
sponse to PRT is variable, and this may be due to muscle inflammation susceptibility. 
Metformin reduces inflammation, so we hypothesized that metformin would augment 
the	muscle	response	to	PRT	in	healthy	women	and	men	aged	65	and	older.	In	a	ran‐
domized,	double‐blind	trial,	participants	received	1,700	mg/day	metformin	(N	=	46)	
or placebo (N	=	48)	throughout	the	study,	and	all	subjects	performed	14	weeks	of	
supervised	PRT.	Although	responses	to	PRT	varied,	placebo	gained	more	lean	body	
mass (p = .003) and thigh muscle mass (p < .001) than metformin. CT scan showed 
that increases in thigh muscle area (p	=	.005)	and	density	(p = .020) were greater in 
placebo versus metformin. There was a trend for blunted strength gains in metformin 
that	did	not	reach	statistical	significance.	Analyses	of	vastus	lateralis	muscle		biopsies	
showed that metformin did not affect fiber hypertrophy, or increases in satellite cell 
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1  | INTRODUC TION
In elderly persons, muscle mass is highly correlated with limited mo‐
bility, disability, and mortality (Han, Bokshan, Marcaccio, DePasse, 
&	Daniels,	2018).	Resistance	exercise	training	(RT)	is	the	most	effec‐
tive therapy for sarcopenia and has been shown to increase muscle 
fiber size, muscle mass, and strength (Taaffe, Pruitt, Pyka, Guido, 
&	Marcus,	1996).	Accordingly,	RT	has	also	been	shown	to	 improve	
activities of daily living, overall health, and quality of life in elderly 
individuals	(Hunter,	McCarthy,	&	Bamman,	2004).	However,	hyper‐
trophic and functional improvements following RT vary among indi‐
viduals, with some people completely failing to experience muscle 
hypertrophy (Stec et al., 2017). Numerous conditions may contribute 
to the nonresponder phenotype in some older adults, including ana‐
bolic	resistance	(Fry	&	Rasmussen,	2011),	chronic	low‐grade	inflam‐
mation	 (Dalle,	 Rossmeislova,	 &	Koppo,	 2017),	 and	muscle‐specific	
inflammation (Merritt et al., 2013).
Metformin has been among the top 10 most widely prescribed 
drugs in the United States for nearly two decades (ClinCalc DrugStats 
Database, clinc alc.com/DrugS tats; Marshall, 2017). Metformin en‐
hances	insulin‐stimulated	glucose	uptake	in	rodents	(Peixoto	et	al.,	
2017)	and	in	muscle	cell	culture	(Galuska,	Nolte,	Zierath,	&	Wallberg‐
Henriksson,	1994),	although	 in	humans	 its	main	effect	 is	 to	 inhibit	
hepatic	glucose	output	(Yu,	Kruszynska,	Mulford,	&	Olefsky,	1999).	
Metformin has also been shown to reduce inflammation in muscle 
(Amin,	Hussein,	Yassa,	Hassan,	&	Rashed,	2018;	Peixoto	et	al.,	2017).	
At	the	tissue	level,	macrophages	are	important	mediators	of	inflam‐
matory	 signaling;	 metformin	 promotes	 polarization	 of	 pro‐inflam‐
matory	M1	macrophages	to	anti‐inflammatory	M2	macrophages	 in	
murine	adipose	tissue	(Amin	et	al.,	2018)	and	bone	marrow‐derived	
monocytes	(Cameron	et	al.,	2016).	We	recently	showed	that	resident	
M2	muscle	macrophages	are	associated	with	exercise‐mediated	in‐
creases	in	skeletal	muscle	satellite	cells	and	fiber	size	(Walton	et	al.,	
2019). In addition, we previously found that resting muscle tissue 
of many older adults is in a heightened, local state of inflammation 
susceptibility (Merritt et al., 2013). Based on these combined data, 
we hypothesized that metformin may improve the muscle response 
to RT by increasing the abundance of M2 macrophages, thereby re‐
ducing muscle inflammation.
In the absence of RT, metformin appears to delay lean mass loss 
in men with type 2 diabetes (Lee et al., 2011). However, when adults 
with prediabetes underwent concurrent aerobic and resistance 
training,	metformin	appeared	to	blunt	exercise‐induced	gains	in	lean	
mass	(Malin,	Gerber,	Chipkin,	&	Braun,	2012).	It	is	unknown	whether	
metformin treatment can augment lean mass gains during RT in 
healthy	 older	 individuals.	 In	 The	Metformin	 to	 Augment	 Strength	
Training	Effective	Response	in	Seniors	(MASTERS)	randomized	trial,	
we determined whether the hypertrophic response to progressive 
RT (PRT) would be improved by the addition of metformin compared 
to placebo (Long et al., 2017).
2  | RESULTS
2.1 | Study participants and design
Baseline	characteristics	of	study	participants	are	given	in	Table	1.	At	
the	University	of	Alabama	at	Birmingham	(UAB),	104	subjects	were	
screened	and	76	were	 randomized.	At	 the	University	of	Kentucky	
(UK),	41	subjects	were	screened	and	33	were	randomized.	Of	109	
randomized	subjects,	15	participants	discontinued	the	study	(n = 6 
due	 to	 adverse	 events),	 resulting	 in	 a	 final	 analytic	 sample	 of	 94	
(86%) who completed the study (n	=	46	Metformin;	n	=	48	Placebo).	
Baseline characteristics and dropout rates were similar between 
treatment	 groups.	 The	Consort	 diagram	 is	 shown	 in	Appendix	 S1:	
Figuer	1.	Among	randomized	subjects,	56%	were	female.	Median	age	
was 69.3 (interquartile range [IQR] 66.9–73.0), and mean BMI was 
26.3 (SD 3.2). The participants tended to be high functioning, with 
a median Short Physical Performance Battery (SPPB) score of 11.0 
(IQR	10–12).	Similarly,	questionnaire‐based	 indices	 suggested	high	
function	in	our	participants:	Median	Physical	Activity	Scale	for	the	
Elderly	 score	was	158.7	 (IQR	124.3–207.9);	median	36‐Item	Short	
Form	 Survey	 Instrument	 (SF‐36)	 Physical	 component	 norm‐based	
score	was	54.8	(IQR	49.4–57.6);	and	median	SF‐36	Mental	compo‐
nent	 norm‐based	 score	 was	 56.5	 (IQR	 53.8–59.2).	 The	 109	 rand‐
omized	subjects	included	105	Caucasians,	three	African	Americans,	
and	one	Asian.
An	overview	of	the	study	design	is	shown	in	Figure	1.	Subjects	
were randomized to receive either placebo or metformin, which 
or macrophage abundance with PRT. However, placebo had decreased type I fiber 
percentage while metformin did not (p	=	.007).	Metformin	led	to	an	increase	in	AMPK	
signaling, and a trend for blunted increases in mTORC1 signaling in response to PRT. 
These results underscore the benefits of PRT in older adults, but metformin nega‐
tively impacts the hypertrophic response to resistance training in healthy older indi‐
viduals. ClinicalTrials.gov Identifier: NCT02308228.
K E Y W O R D S
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was titrated up to the target dose of 1,700 mg/day, consistent 
with doses that are prescribed for diabetes and prediabetes (Hess, 
Unger,	Madea,	Stratmann,	&	Tschoepe,	2018),	for	the	duration	of	
the	 trial.	Following	a	2‐week	drug	wash‐in	period,	 and	a	2‐week	
PRT	 familiarization	 and	 ramp‐up	 period,	 baseline	 strength	 test‐
ing	 was	 performed.	 All	 participants	 then	 continued	 to	 perform	
12 more weeks of supervised, variable intensity, bilateral, upper, 
and lower body PRT. Participants received metformin or placebo 
for	 the	entire	duration	of	PRT	and	 through	post‐training	assess‐
ments.	Dual‐energy	X‐ray	absorptiometry	(DXA)	scans,	mid‐thigh	
computed tomography (CT) scans, muscle biopsies, and oral glu‐
cose tolerance tests were performed at baseline and 3 days after 
the final exercise bout, to assess chronic effects of the interven‐
tion.	While	60%	of	participants	who	completed	the	placebo	arm	
were	 female,	48%	of	participants	who	completed	 the	metformin	
arm	were	female.	Although	sex	distribution	was	not	significantly	
different between groups (χ2 (df	 =	 1)	 =	 1.50,	 p = .221), the sex 
distribution led to significant differences in baseline measures. To 
account for sex differences at baseline and following training, we 
compared percent changes in all measured outcome variables ex‐
cept	 for	 those	 that	were	already	percent‐based	 (percent	 fat	 and	
percent fiber type frequency).
Medication	and	exercise	compliance	data	are	given	in	Appendix	
S1.	 Adverse	 events	 were	 more	 likely	 to	 occur	 with	 metformin	
(χ2 (df = 1) = 9.82, p	=	.002)	(Appendix	S1:	Table	1).	Deviations	from	
the study protocol included randomization of 13 obese subjects (BMI 
30–33.9).	Additionally,	five	subjects	completed	fewer	than	37	exer‐
cise	sessions	prior	to	undergoing	the	final	muscle	biopsy.	A	summary	
and	explanation	of	missing	data	are	given	in	Appendix	S1:	Table	2.
Nearly all participants underwent some beneficial physiological 
adaptations	 in	 response	 to	 PRT.	 Appendix	 S2:	 Table	 1	 shows	 the	
effect of PRT for all measured outcomes in those who completed 
the	trial.	Appendix	S2:	Table	2	shows	the	effects	of	PRT	within	each	
treatment group.
TA B L E  1   Baseline characteristics of study participants
 Placebo Metformin
Randomized N	=	55 N	=	54
Discontinued 7 (13%) 8	(15%)
Site
Lexington, KY 17 (31%) 16 (30%)
Birmingham,	AL 38 (69%) 38 (70%)
Sex, all randomized participants
Female 32	(58%) 29	(54%)
Male 23	(42%) 25	(46%)
Sex, participants who completed the study
Female 29 (60%) 22	(48%)
Male 19	(40%) 24	(52%)
Age
median (IQR), range
69.3 
(66.8–74.0),	
64.4–82.8
69.4	(66.8–72.3),	
64.8–91.2
BMI
mean (SD), range
25.7	(3.1),	
18.6–30.3
26.9 (3.1), 
20.2–33.9
Function
Short Physical Performance 
Battery (SPPB)
median (IQR), range
11 (11–12), 
7–12
11	(10–12),	5–12
Physical	Activity	Scale	for	
the	Elderly	(PASE)
median (IQR), range
165.7	
(133.4–210.5),	
52.5–348.2
155.5	
(115.8–207.4),	
55.0–492.0
36‐Item	Short	Form	(SF−36)	
Physicala 
median (IQR), range
55.2	
(49.5–57.6),	
35.0–62.4
54.7	(49.1–57.5),	
27.9–67.9
36‐Item	Short	Form	(SF−36)	
Mentala 
median (IQR), range
56.5	
(54.6–59.1),	
40.7–63.0
56.7	(52.3–59.3),	
17.5–65.5
aComponent	norm‐based	score.	
F I G U R E  1  A	schematic	representation	of	the	study	design.	CT,	
computed	tomography;	DXA,	dual‐energy	X‐ray	absorptiometry;	
OGTT, oral glucose tolerance test; PRT, progressive resistance 
training
2 weeks
Metformin
1,700 mg/day Placebo
PRT ramp-up 
phase with 
continued 
placebo
MASTERS double-blind 
randomized controlled trial design
Strength testing
OGTT, DXA, 
thigh CT scan,
muscle biopsy 
48 completed 
placebo
2 weeks
+
OGTT, physical function, 
DXA, thigh CT scan,
muscle biopsy 
Baseline strength testing
12 weeks
+
46 completed 
metformin
Ongoing PRT
with continued 
placebo
PRT ramp-up 
phase with 
continued 
metformin
Ongoing PRT
with continued 
metformin
3 days without PRT
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2.2 | Metformin inhibits PRT‐induced gains in total 
lean mass and thigh muscle mass; metformin trends 
toward inhibiting strength gains
Changes in body weight, diet, and glucose metabolism are shown in 
Appendix	S3.	PRT	induced	weight	loss	in	most	participants,	with	no	
effect of metformin. Dietary intake was not affected by PRT, with or 
without	metformin	(Appendix	S3:	Table	1).	Although	fasting	glucose	
was	decreased	in	placebo	by	−3.35%	(SD	7.46)	(p = .003), metformin 
had	a	mean	nonsignificant	decrease	of	−1.59%	(SD 7.99) (p	=	.184);	
nonetheless, changes in fasting glucose did not differ between treat‐
ment groups (p	=	.272)	(Appendix	S2:	Table	2;	Appendix	S3:	Table	1).	
Insulin sensitivity was improved by PRT in both groups, with no sig‐
nificant	difference	between	groups	(Appendix	S2:	Table	2;	Appendix	
S3: Table 1).
We	used	DXA	to	assess	body	composition	at	baseline	and	after	
PRT (Figure 2). PRT led to a reduction in percent fat, with no differ‐
ence	between	groups;	mean	decrease	in	percent	fat	was	−1.86	(SD 
2.08)	with	 placebo	 and	 −2.02	 (SD	 1.95)	with	metformin	 (between	
groups p	=	 .714)	 (Figure	2a).	However,	metformin	prevented	gains	
in lean mass with PRT (between groups p = .003); placebo gained 
1.95%	 (SD 2.69) lean mass (p	<	 .001),	while	 the	0.41%	change	 (SD 
2.25)	in	metformin	did	not	reach	significance	(p = .218) (Figure 2b; 
Appendix	S2:	Table	2).	Metformin	also	blocked	 thigh	muscle	mass	
gains (between groups p < .001), with placebo gaining 3.90% (SD 
5.54)	(p	<	.001),	and	metformin	showing	no	significant	gain	(0.45%,	
SD	3.95)	(p	=	.441)	(Figure	2c;	Appendix	S2:	Table	2).
With	PRT,	increases	in	strength	tended	to	be	lower	with	met‐
formin, but differences were not statistically significant (Table 2). 
Knee extension 1 repetition maximum (RM) increased 23.1% (SD 
18.9)	 in	 placebo	 and	 15.3%	 (SD	 18.5)	 in	 metformin	 (between	
groups p	 =	 .055);	 knee	 extension	 isometric	 strength	 increased	
11.8% (SD 12.7) with placebo compared to 6.7% (SD	 14.5)	with	
metformin (between groups p = .082); and peak knee extension 
power	 increased	 29.4%	 (SD	 40.7)	 in	 placebo	 versus	 14.3%	 (SD 
35.7)	 in	metformin	 (between	groups	p	=	 .064).	Relative	strength	
(knee extension kg/bilateral thigh muscle mass kg) gains following 
PRT were similar in both groups, with placebo improving 19.7% (SD 
19.0)	and	metformin	 improving	14.5%	(SD 17.9) (between groups 
p = .188).
2.3 | Metformin did not affect vastus lateralis fiber 
hypertrophy; metformin inhibited decreases in type I 
fiber frequency
Fiber	 cross‐sectional	 area	 (CSA)	was	determined	by	 immunohisto‐
chemistry for type I fibers, type II fibers, and fiber borders (laminin) 
in vastus lateralis (VL) biopsies (Figure 3a). Metformin did not affect 
type	 I	 fiber	CSA	with	PRT;	mean	change	 in	 type	 I	CSA	was	7.64%	
(SD 31.6) in placebo and 1.30% (SD 23.1) in metformin (between 
groups p = .379) (Figure 3b). Metformin also did not affect type II 
fiber	 hypertrophy	with	 PRT;	mean	 type	 II	 CSA	 change	 in	 placebo	
was	18.5%	(SD	31.5)	versus	14.5%	(SD 29.7) in metformin (between 
groups p = .610) (Figure 3c). Since metformin inhibited lean mass 
gains	measured	 by	DXA,	we	 assessed	whether	 changes	 in	 type	 II	
fiber	CSA	accurately	reflect	changes	in	bilateral	thigh	muscle	mass	
(by	DXA).	There	was	a	trend	toward	a	positive	correlation	between	
changes	 in	 type	 II	 fiber	 CSA	 and	 thigh	 muscle	 mass	 (R2 = 0.071, 
p	=	.058)	(Appendix	S4:	Figure	1a).
Metformin inhibited shifts in fiber type frequency following PRT. 
Metformin prevented decreased type I fiber frequency with PRT 
(between groups p = .007); placebo decreased type I fiber frequency 
by 6.06% (SD	 11.5)	 (p = .007), while metformin had a nonsignifi‐
cant	increase	of	2.50%	(SD	12.4)	(p	=	.278)	(Figure	3d;	Appendix	S2:	
Table 2). Both groups gained type IIa fiber frequency, with placebo 
increasing by 12.9% (SD	12.6),	and	metformin	 increasing	by	7.48%	
(SD 17.0) (between groups p = .167) (Figure 3d). Both groups also had 
similar decreases in type IIx/IIax fiber frequency following PRT, with 
placebo	decreasing	by	−7.49%	(SD	14.4)	and	metformin	decreasing	
by	−10.1%	(SD	15.0)	(between	groups	p	=	.493)	(Figure	3d).
F I G U R E  2   Metformin does not affect decreases in percent fat, but blunts gains in lean mass and thigh muscle mass following PRT. 
Body	composition	and	bilateral	thigh	muscle	mass	were	measured	using	DXA.	N	=	48	placebo,	46	metformin.	(a)	With	PRT,	percent	fat	was	
reduced in most participants, and this reduction was not affected by metformin (p	=	.714).	(b)	Percent	change	in	lean	mass	was	larger	in	
placebo than in metformin (p = .003), and (c) percent change in thigh muscle mass was also larger in placebo than in metformin (p < .001). 
Student's t	test.	Box	plots	indicate	the	mean	(×)	and	median	(‐	‐	‐	‐	‐	‐	‐	‐),	and	whiskers	indicate	the	upper	and	lower	quartiles
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F I G U R E  3  With	PRT,	metformin	does	not	affect	fiber	hypertrophy,	but	inhibits	increased	type	I	fiber	frequency,	without	significantly	
affecting	satellite	cell	expansion.	Immunohistochemistry	on	pre‐	and	post‐PRT	biopsies	was	performed	in	30	subjects/group.	(a)	
Representative immunoflourescent fiber typing, showing staining of type I myosin heavy chain (purple), type IIax myosin heavy chain (green), 
type IIx myosin heavy chain (red), and laminin for fiber borders (blue). Type I/II hybrid fibers were excluded from analyses. (b) Percent 
change	in	type	I	fiber	CSA	was	negligible	and	was	not	affected	by	metformin	(p = .379). (c) PRT caused type II fiber hypertrophy in most 
subjects,	and	percent	change	in	type	II	fiber	CSA	was	not	affected	by	metformin	(p = .610). (d) Changes in fiber type frequency (percent fiber 
type):	While	placebo	had	reduced	type	I	fiber	frequency	following	PRT,	metformin	blunted	this	adaptation	(p = .007); however, metformin 
did not affect increases in type IIa fiber frequency (p = .167), or decreases in type IIx/IIax fiber frequency (p	=	.493).	(e)	Representative	
immunoflourescent	stain	for	fiber	type‐specific	satellite	cells,	using	Pax7	to	identify	satellite	cells	(red),	laminin	for	fiber	borders	(green),	
type	I	myosin	heavy	chain	(purple),	and	DAPI	for	nuclei	(blue).	The	red	carrot	indicates	a	type	II	fiber‐associated	satellite	cell.	(f)	Compared	to	
placebo,	metformin	had	an	increased	mean,	but	not	significant,	percent	change	in	type	I‐associated	satellite	cells/type	I	fibers	(p = .088). (g) 
The	percent	change	in	type	II‐associated	satellite	cells/type	II	fibers	was	not	affected	by	metformin.	Student's	t test. Box plots indicate the 
mean	(×)	and	median	(‐	‐	‐	‐	‐	‐	‐	‐),	and	whiskers	indicate	the	upper	and	lower	quartiles
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2.4 | Metformin did not affect increases in 
satellite cells
Our group has previously shown that satellite cell (muscle stem cell) 
accretion	is	associated	with	fiber	hypertrophy	(Fry	et	al.,	2014;	Petrella,	
Kim,	Mayhew,	 Cross,	 &	 Bamman,	 2008).	We	 therefore	 determined	
whether	metformin	would	affect	fiber	type‐specific	satellite	cell	con‐
tent using immunohistochemistry for Pax7, type I fibers, and fiber 
borders (laminin) (Figure 3e). Following PRT, there was a trend toward 
greater	 increases	 in	 type	 I‐associated	 satellite	 cells	with	metformin.	
Placebo	increased	type	I‐associated	satellite	cells/type	I	fiber	by	16.1%	
(SD	48.0),	while	metformin	increased	type	I‐associated	satellite	cells/
type	I	fiber	by	39.4%	(SD	56.0)	(between	groups	p = .088) (Figure 3f). 
Type	II‐associated	satellite	cell	accretion	did	not	differ	between	groups,	
with placebo increasing by 33.0% (SD 79.1) and metformin increasing 
by 32.1% (SD	47.8)	(between	groups	p	=	.957)	(Figure	3g).
2.5 | Metformin inhibits PRT‐induced increases in 
thigh muscle cross‐sectional area and density
Metformin	blocked	PRT‐induced	gains	 in	 lean	mass	by	DXA.	Thus,	
we	determined	whether	increases	in	thigh	muscle	CSA	and	density,	
assessed	by	mid‐thigh	CT	 scans,	would	 be	 affected	 by	metformin	
treatment	 (Figure	4).	Decreases	 in	 low‐density	muscle,	which	con‐
tains more intramyocellular lipid than normal density muscle, were 
similar	 between	 groups,	 with	 placebo	 losing	 −6.74%	 (SD 11.6), 
and	metformin	 losing	−3.86%	(SD 10.6) (between groups p	=	 .257)	
(Table 2). However, placebo gained significantly more normal density 
muscle	area	 than	metformin,	with	a	mean	gain	of	10.5%	 (SD 7.01) 
with	placebo	versus	4.16%	(SD 9.11) with metformin (between groups 
p = .001) (Table 2). Since the thigh muscles contain more normal than 
low‐density	muscle,	placebo	gained	significantly	more	total	muscle	
area	than	metformin.	Mean	gain	in	total	muscle	area	was	6.43%	(SD 
5.45)	with	placebo,	versus	2.27%	(SD 6.91) with metformin (between 
groups p	=	.005)	(Figure	4a).	With	resistance	training,	mean	changes	
in	type	II	fiber	CSA	and	CT	thigh	muscle	area	have	been	shown	to	
be comparable (Nilwik et al., 2013). Thus, we assessed the accuracy 
of these measures in our cohort and found a significant positive cor‐
relation	between	mean	changes	 in	 type	 II	 fiber	CSA	and	CT	 thigh	
muscle area (R2 = 0.116, p	=	.014)	(Appendix	S4,	Figure	1b).	However,	
changes	 in	 thigh	muscle	mass	 (by	DXA)	and	changes	 in	 total	 thigh	
muscle area (by CT) were more tightly associated with each other 
(R2	=	0.325,	p	<	.0001)	(Appendix	S4,	Figure	1c)	than	with	changes	
in	type	II	fiber	CSA.	Consistent	with	lower	gains	in	normal	density	
muscle area, metformin displayed a significantly smaller increase in 
average	muscle	density;	placebo	increased	muscle	density	by	4.13%	
(SD	3.27),	while	metformin	increased	muscle	density	by	2.49%	(SD 
2.75)	(between	groups	p	=	.020)	(Figure	4b).
2.6 | Metformin does not affect muscle macrophage 
increases with PRT
We	originally	hypothesized	that	metformin	would	enhance	skeletal	
muscle	 hypertrophy	 by	 increasing	 resident	M2	 macrophages.	We	
therefore	 performed	 immunohistochemistry	 for	 anti‐inflamma‐
tory M2 macrophages (CD11b+/CD206+) and total macrophages 
(CD11b+) in VL biopsies obtained before and after the intervention 
(Figure	5a).	Although	both	cell	populations	increased	following	PRT,	
neither was affected by metformin. CD11b+/CD206 + macrophages 
increased	by	53.6%	(SD	66.3)	in	placebo	and	by	57.3%	(SD	48.6)	in	
metformin (between groups p	=	.804)	(Figure	5b).	Total	macrophages	
increased	by	50.9%	(SD	64.6)	with	placebo	and	by	51.0%	(SD	50.6)	
with metformin (between groups p	=	.999)	(Figure	5c).
2.7 | Chronic metformin administration increases 
basal AMPK and ACC phosphorylation while blunting 
RPS6 activation following PRT
Acute	resistance	exercise	transiently	activates	AMPK;	however,	met‐
formin inhibits mitochondrial complex I, causing decreased cellular 
F I G U R E  4   Metformin blunts increased 
thigh muscle area and density resulting 
from PRT. Using CT, we assessed thigh 
muscle	cross‐sectional	area	(cm2) and 
density (Hounsfield Units, HU), using the 
average of both legs. N	=	40	placebo,	
37 metformin. (a) The percent change in 
thigh muscle area was significantly larger 
in placebo versus metformin (p	=	.005),	
and (b) placebo also had a larger percent 
change in thigh muscle density (p = .020). 
Student's t test. Box plots indicate the 
mean	(×)	and	median	(‐	‐	‐	‐	‐	‐	‐	‐),	and	
whiskers indicate the upper and lower 
quartiles
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energy	availability,	and	ultimately	leading	to	chronic	AMPK	activa‐
tion (Musi et al., 2002). In order to determine whether metformin 
affects	chronic	AMPK‐mediated	signaling	in	the	context	of	PRT,	we	
used	Western	blots	 to	quantify	 the	phosphorylation	of	AMPK,	 its	
downstream	target	ACC,	and	RPS6,	a	downstream	target	of	mTORC1	
in	VL	biopsies	from	15	subjects/group.	With	PRT,	the	mean	ratio	of	
phospho‐AMPK:total	AMPK	was	increased	by	1.6%	(SD 8.8) in pla‐
cebo and by 21.3% (SD 6.6) in metformin (between groups p = .087) 
(Figure	 6a).	 Consistent	 with	 chronic	 AMPK	 activation,	 metformin	
had	a	significantly	larger	increase	in	ACC	phosphorylation.	Phospho‐
ACC	increased	by	6.2%	(SD	7.9)	with	placebo,	versus	42.2%	(SD 13.9) 
with metformin (between groups p	 =	 .035)	 (Figure	 6b).	 Following	
PRT, RPS6 phosphorylation increased by 73.1% (SD 22.6) in pla‐
cebo and by 29.9% (SD 8.2) in metformin (between groups p = .090) 
(Figure 6c,d).
We	next	modeled	exercise	in	primary	human	myotubes	in	order	
to	determine	whether	metformin	affects	AMPK	and	mTORC1	signal‐
ing in response to an anabolic exercise stimulus. Human myogenic 
F I G U R E  5  Metformin	does	not	affect	increases	in	skeletal	muscle	macrophages	with	PRT.	Immunohistochemistry	on	pre‐	and	post‐PRT	
biopsies was performed in 30 subjects/group. (a) Representative immunoflourescent macrophage identification, showing staining for CD11b 
(green),	CD206	(red),	and	DAPI	for	nuclei	(blue).	The	green	carrot	indicates	a	CD11b	+	macrophage,	and	the	yellow	carrots	indicate	CD11b+/
CD206	+	macrophages.	When	given	with	PRT,	metformin	did	not	affect	the	percent	change	in	(b)	CD11b+/CD206	+	macrophages	per	fiber	
(p	=	.804),	or	in	(c)	all	CD11b	+	macrophages	per	fiber	(0.999).	Student's	t	test.	Box	plots	indicate	the	mean	(×)	and	median	(‐	‐	‐	‐	‐	‐	‐	‐),	and	
whiskers indicate the upper and lower quartiles
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F I G U R E  6  Metformin	administration	with	PRT	increases	mean	basal	AMPK	and	ACC	phosphorylation,	and	blunts	mean	RPS6	activation	
following	PRT.	Western	blotting	was	performed	on	baseline	and	post‐PRT	vastus	lateralis	biopsies	from	15	subjects/group.	One	placebo	
outlier	was	removed	from	AMPK	analysis.	(a)	Following	PRT,	metformin	had	a	higher	percent	change	in	basal	phospho‐AMPK:total	AMPK	
ratio that did not reach statistical significance (p = .087). (b) The metformin group also had a significantly higher percent change in basal 
phospho‐ACC:total	ACC	ratio	following	PRT	(p	=	.035).	(c)	The	placebo	group	had	a	greater	mean	increase	in	basal	phospho‐RPS6:total	RPS6	
ratio that did not reach statistical significance (p	=	.090).	(d)	Representative	Western	blots	of	human	muscle	biopsies.	(e)	In	cultured	human	
myotubes, treatment with metformin blunts phosphorylation of p70S6K1 following electrical stimulation. Student's t test. Box plots indicate 
the	mean	(×)	and	median	(‐	‐	‐	‐	‐	‐	‐	‐),	and	whiskers	indicate	the	upper	and	lower	quartiles
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progenitor cells were differentiated into myotubes and treated with 
metformin	during	8	hr	of	high‐frequency	electrical	pulse	stimulation	
(Tarum,	Folkesson,	Atherton,	&	Kadi,	2017).	Western	blots	were	used	
to	quantify	phospho‐AMPK:total	AMPK	and	phospho‐p70S6K1:to‐
tal p70S6K1 (an immediate target of mTOR). Consistent with chronic 
changes	in	VL	biopsies,	metformin	induced	greater	phospho‐AMPK	
in cultured myotubes, irrespective of whether they received electri‐
cal stimulation. Following electrical stimulation, metformin inhibited 
mean p70S6K1 phosphorylation (Figure 6e).
3  | DISCUSSION
In	men	 and	women	 aged	 65	 and	 older,	 14	weeks	 of	 PRT	 induced	
the expected increases in muscle mass and strength. However, 
metformin	administered	along	with	PRT	inhibited	these	gains.	DXA	
showed that metformin gained significantly less total lean mass and 
less thigh muscle mass than placebo. Likewise, CT analysis indicated 
that normal density thigh muscle area increased following PRT, but 
metformin blunted this gain. Our observations are consistent with 
Malin	et	al.	(2012),	who	reported	that	metformin	inhibits	gains	in	fat‐
free mass in response to concurrent aerobic and resistance training 
in subjects with prediabetes.
Metformin may inhibit muscle hypertrophy via inhibition of 
mTORC1, leading to decreased muscle protein synthesis or increased 
autophagy.	Metformin	indirectly	activates	AMPK,	a	major	mTORC1	
inhibitory kinase, leading to reduced hypertrophy in muscle cell cul‐
ture	 and	 rodents	 (Kwon	 &	Querfurth,	 2015;	 Lantier	 et	 al.,	 2010).	
In	 human	muscle,	metformin	 reduces	 the	 expression	 of	mTORC1‐
related genes in older individuals with impaired glucose tolerance 
(Kulkarni et al., 2018). In keeping with these data, we observed lower 
mean RPS6 activation in participants randomized to metformin and 
inhibition of p70S6K1 phosphorylation in cultured myotubes follow‐
ing metformin treatment during electrical pulse stimulation. Thus, 
acute and/or chronic blunting of mTORC1 activation may contribute 
to	the	decreased	lean	mass	gains	in	metformin‐treated	subjects.
Strength and power also increased in response to PRT, but we 
found trends for blunted gains with metformin treatment. Boule et 
al. (2013) reported that following 22 weeks of resistance training 
in	middle‐aged	subjects	with	 type	2	diabetes,	metformin	 inhibited	
muscle mass gains without affecting strength. Since our study nei‐
ther confirms nor contradicts Boule et al., additional studies are war‐
ranted to determine how metformin affects strength.
Although	 muscle	 mass	 gains	 with	 PRT	 were	 lower	 with	 met‐
formin,	 it	 did	 not	 affect	 changes	 in	muscle	 fiber	 CSA.	One	 study	
reported that following resistance training, increased type II fiber 
CSA	drives	increases	in	thigh	muscle	area	(by	CT),	but	this	paper	re‐
ported mean changes for the entire cohort rather than correlations 
between the techniques (Nilwik et al., 2013). In another report, VL 
volume	was	not	correlated	with	increased	fiber	CSA	in	young	men	
following resistance training (Mobley et al., 2018). Compared to 
measures	of	whole	muscle	size,	measures	of	fiber	CSA	are	probably	
more vulnerable to sampling and technical error, causing increased 
variance and decreasing statistical power. This idea is supported 
by	our	supplemental	data	showing	that	CT	and	DXA	measures	are	
highly	correlated	with	each	other,	while	fiber	CSA	measures	are	not	
as	highly	correlated	with	CT	or	DXA.	These	data	suggest	that	CT	and	
DXA	may	be	more	 reliable	 indicators	 of	muscle	 hypertrophy	 than	
fiber	CSA.	Metformin	also	did	not	affect	decreases	in	type	IIx/IIax	
fiber frequency, nor gains in satellite cells or resident macrophage 
abundance. It is therefore unlikely that changes in these parameters 
contribute to altered PRT responses with metformin.
Metformin blunted reductions in the frequency of type I fibers, 
which	 typically	 contain	more	 lipid	 than	 type	 II	 fibers	 (Schrauwen‐
Hinderling,	 Hesselink,	 Schrauwen,	 &	 Kooi,	 2006).	 Furthermore,	
placebo had significantly larger improvements in muscle density, 
assessed by CT. Since lower tissue density is associated with a more 
lipid‐rich	environment,	these	findings	suggest	a	greater	decrease	in	
muscle lipid content in placebo following PRT. Metformin inhibits 
mitochondrial complex I (Fontaine, 2018), which could lead to inhi‐
bition of fatty acid oxidation and increased intramyocellular lipid. 
Although	studies	in	sedentary	humans	have	shown	either	no	effect	
(Rasouli	et	al.,	2005)	or	decreased	(Teranishi	et	al.,	2007)	intramyo‐
cellular lipid following metformin treatment, the increased metabolic 
demands during PRT may require increased mitochondrial complex I 
activity, and metformin may interfere with this process. Considering 
that	 we	 also	 observed	 increased	 phosphorylation	 of	 AMPK	 and	
ACC	(which	should	promote	lipid	oxidation)	in	metformin	following	
PRT,	we	 suspect	 that	metformin‐mediated	 inhibition	 of	 complex	 I	
counteracts	and	overrides	the	effects	of	AMPK	activation,	 leading	
to decreased lipid oxidation. Consistent with this idea, metformin 
was	 recently	 shown	 to	 abrogate	 aerobic	 exercise	 training‐induced	
increases in skeletal muscle mitochondrial respiration in older adults 
(Konopka et al., 2018).
Other outcome measures included body weight, diet, and glu‐
cose	metabolism.	 Both	 groups	 lost	 weight	 following	 14	 weeks	 of	
PRT, and metformin did not affect weight loss. Furthermore, neither 
PRT nor metformin affected total daily caloric or protein intake, indi‐
cating that our observations cannot be explained by dietary changes. 
Although	the	metformin‐treated	subjects	reported	more	GI	side	ef‐
fects, this did not result in discontinuation of drug and did not af‐
fect exercise adherence in our generally healthy senior population. 
Metformin also did not affect changes in fasting glucose, glucose 
tolerance, or insulin sensitivity, all of which improved in response to 
PRT. It is noteworthy that metformin inhibits improved insulin sensi‐
tivity with endurance training (Konopka et al., 2018), indicating that 
resistance and endurance training may improve insulin sensitivity 
through differing mechanisms.
One limitation of our trial is that it did not include sedentary 
control groups. Therefore, we are unable to draw conclusions re‐
garding the effects of metformin alone on muscle mass and strength 
in generally healthy older adults. The effects of metformin in frail 
elderly, alone or in combination with resistance exercise, need fur‐
ther	 study.	Although	metformin	 appears	 to	 preserve	 lean	mass	 in	
sedentary diabetic patients (Lee et al., 2011), it would be important 
to know whether metformin affects muscle mass and strength gains 
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with PRT in older diabetic patients. Our study was not designed to 
address these issues, and the majority of our cohort was nonobese 
and free from metabolic disease.
In	 conclusion,	 14	weeks	 of	 progressive	 resistance	 training	 re‐
sulted in variable, but significant, gains in total lean mass and thigh 
muscle	mass	 in	 healthy	 adults	 aged	65	 and	over.	However,	 these	
gains	were	blunted	by	metformin	 administration.	While	 relatively	
few studies have addressed the combined effects of exercise and 
metformin in humans, all current data indicate that metformin 
blunts some of the beneficial effects of endurance, resistance, or 
combined	exercise	 training	 (reviewed	 in	Konopka	&	Miller,	2019).	
Although	 metformin	 is	 highly	 effective	 for	 the	 prevention	 and	
treatment of diabetes, these results do not support the use of met‐
formin to enhance the benefits of physical activity in healthy el‐
derly people.
4  | E XPERIMENTAL PROCEDURES
4.1 | Design, setting, and participants
The	 MASTERS	 was	 a	 randomized,	 controlled,	 double‐blind	 trial	
comparing the effects of metformin versus placebo during pro‐
gressive	 resistance	 training	 (PRT)	 in	 community‐dwelling	 sen‐
iors. Participants were recruited in Lexington, Kentucky (UK) and 
Birmingham,	Alabama	(UAB),	and	the	protocol	was	approved	by	both	
IRBs via IRB Share. Data collection and study interventions occurred 
at	both	UK	and	UAB.	The	study	design	is	provided	in	Figure	1	and	in	
our previous publication (Long et al., 2017). The consort diagram is 
shown	in	Appendix	S1:	Figure	1.
Men and women were eligible to participate whether they were 
aged	65	and	over,	independently	mobile,	had	a	SPPB	(Guralnik	et	al.,	
1994)	score	of	4–12,	and	were	nondiabetic.	To	be	included,	partici‐
pants had to have transportation, and to be cognitively intact and ca‐
pable	of	providing	written	informed	consent.	Appendix	S5	provides	
recruitment methods and exclusion criteria.
4.2 | Interventions
Subjects were randomized to receive either placebo or metformin 
for the duration of the trial. Randomization permutation and blinding 
procedures	are	described	in	Appendix	S5.	Subjects	underwent	a	2‐
week	drug	or	placebo	wash‐in	period	prior	to	beginning	PRT.	Those	
who were randomized to metformin were titrated up to the target 
dose	by	taking	1	tablet	per	day	(850	mg)	for	7	days,	followed	by	2	
tablets per day (1,700 mg) for the remainder of the trial.
All	 study	 subjects	 underwent	14	weeks	of	PRT,	 supervised	by	
trained personnel. In order to train all muscle groups, every work‐
out consisted of the following bilateral, constant load movements: 
leg press, knee extension, body weight squat progressing to a split 
squat, calf press, chest press, lat pull down, biceps curl, and tri‐
ceps	 press	 down.	 We	 employed	 a	 variable	 intensity	 prescription	
across the three training days each week (high/low/high) based on 
the results of our previous dose–response trial which showed this 
prescription optimized strength and muscle mass gains in older 
adults	(Stec	et	al.,	2017).	Thus,	participants	performed	high‐intensity	
workouts on Mondays and Fridays; they completed 3 sets of 8–12 
repetitions	 at	 their	 10	 repetition	maximum	 (10RM)	 load,	with	 60‐	
to	90‐s	rests	between	sets.	On	Wednesdays,	resistance	loads	were	
reduced ~ 30% and subjects performed rapid concentric contrac‐
tions with controlled eccentric loading in order to develop explosive 
power. Continuous progression was incorporated by increasing the 
resistance load when subjects were able to perform 12 repetitions 
for 2 of 3 sets on “high” days. Participants were considered com‐
pliant	with	the	exercise	protocol	if	they	completed	42	±	5	exercise	
sessions, including at least three exercise sessions (high/low/high) in 
a	row	before	follow‐up	testing.
All	 outcome	 measures,	 except	 for	 strength	 testing,	 were	 per‐
formed at baseline, prior to drug initiation, and 3 days after the final 
bout of training. In order to account for neuromuscular adaptation, 
baseline strength testing was performed after 2 weeks after PRT 
initiation.
4.3 | Body weight, nutrition, and 
glucose metabolism
We	assessed	changes	in	body	weight,	diet,	and	glucose	metabolism	
following	PRT	with	placebo	or	metformin.	At	baseline	and	week	16,	
subjects	completed	≥	3	consecutive	days	of	diet	records,	which	were	
analyzed with the Nutrition Data System for Research software pub‐
lished	by	the	University	of	Minnesota	(Schakel,	2001).	Also	at	base‐
line	and	week	16,	 standard	2‐hr	oral	glucose	 tolerance	 tests	were	
performed	and	the	Matsuda	index	(Matsuda	&	DeFronzo,	1999)	was	
used to calculate insulin sensitivity. The detailed oral glucose toler‐
ance	protocol	is	provided	in	Appendix	S5.
4.4 | Body composition and strength
Dual‐energy	 X‐ray	 absorptiometry	 scans	 were	 performed	 using	
a	 GE	 Lunar	 iDXA	 at	 baseline	 and	 week	 16	 in	 order	 to	 measure	
changes	 in	whole‐body	 lean	 and	 fat	mass,	 percent	 fat,	 and	 thigh	
muscle	mass.	Scans	were	analyzed	using	the	GE	Lunar	software	ver‐
sion 10.0.
Leg	 strength	was	measured	 at	week	 4	 (after	 2	weeks	 of	 PRT)	
and week 16. Voluntary, dynamic strength was determined using 1 
repetition maximum (1RM), defined as the maximal load that a sub‐
ject can lift at one time, with proper form, through a full range of 
motion	(Petrella,	Kim,	Tuggle,	Hall,	&	Bamman,	2005).	After	warming	
up, subjects performed single repetition trials with increasing resis‐
tance until they failed two attempts at a given load. The last load 
lifted with good form was recorded as the 1RM. Maximum voluntary 
isometric	knee	extension	strength	was	measured	using	a	Biodex	4	
dynamometer. To control for neuromuscular adaptations that occur 
in	the	early	phases	of	resistance	training	(Moritani	&	deVries,	1979),	
week	4	(after	2	weeks	of	resistance	training)	was	used	as	the	base‐
line measure for calculating changes in strength. To calculate relative 
strength,	knee	extension	1RM	was	normalized	to	DXA	bilateral	thigh	
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muscle	mass	 (Goodpaster	et	al.,	2006).	Additional	strength	testing	
methods	are	provided	in	Appendix	S5.
4.5 | Computed tomography
Computed tomography was used to measure changes in whole thigh 
muscle	size	and	density.	At	baseline	and	week	16,	CT	images	were	
obtained	from	the	mid‐thigh	(defined	as	the	midpoint	between	the	
inguinal crease and proximal border of the patella). CT scans were 
analyzed	to	delineate	thigh	muscle	and	to	determine	the	CSA	of	low‐
density	muscle	(0–34	Hounsfield	Units	[HU]),	normal	density	muscle	
(35–100	HU),	and	those	areas	combined	(0–100	HU).	Mean	attenua‐
tion	(HU)	across	the	mid‐thigh	muscle	area	that	included	0–100	HU	
muscle	 was	 also	 determined.	 Additional	 CT	methods	 are	 given	 in	
Appendix	S1.
4.6 | Cell culture
Human myogenic progenitor cells were isolated and passaged 
as	 described	 (Latroche,	 Weiss‐Gayet,	 Gitiaux,	 &	 Chazaud,	 2018)	
(Appendix	S5).	Cells	were	isolated	from	the	VL	of	two	elderly	sub‐
jects	 (age	 >65	 years).	 Cells	were	 differentiated	 into	myotubes	 for	
5	 days	 using	 MyoCult	 serum‐free	 differentiation	 media	 (Stemcell	
Technologies). On the fifth day, fresh media with 10 mM metformin 
(Sigma‐Aldrich)	 or	 vehicle	 (PBS)	was	 added	 just	 prior	 to	 electrical	
pulse stimulation. Cells were then stimulated at 12 V, 1 Hz, 2 ms 
for	8	hr	 (EPS,	 IonOptix	C‐Pace	EP),	 followed	by	 immediate	protein	
extraction	 in	RIPA	buffer	 (ThermoFisher)	plus	Halt	protease/phos‐
phatase	 inhibitor	 (ThermoFisher)	 for	Western	blot	 analyses	as	de‐
scribed below.
4.7 | Immunohistochemistry and western blotting
At	baseline	and	week	16,	muscle	biopsies	were	taken	from	the	VL	
using	a	5‐mm	Bergstrom	needle	with	suction.	A	portion	of	each	VL	
biopsy was mounted in tragacanth gum and frozen for immunohis‐
tochemistry	on	fresh	frozen	sections.	Antibodies	against	type	I,	type	
IIax, and type IIx myosin heavy chain were used to distinguish fiber 
types, and antilaminin was used to identify fiber borders. Type I/
IIa	hybrid	fibers	were	excluded	from	all	analyses.	Fiber	type‐specific	
satellite cells were identified using antibodies against Pax7, type I 
myosin heavy chain, and laminin. Macrophages were identified using 
antibodies against CD11b and CD206. The largest, highest quality 
pairs of baseline and week 16 mounts were used for quantification 
of immunohistochemistry (N = 30/group). Detailed methods are 
given	 in	 Appendix	 S5	 and	 in	 our	 previous	 publications	 (Fry	 et	 al.,	
2014;	Kosmac	et	al.,	2018).
In a subset of participant biopsies (N	=	15/group),	we	performed	
Western	blots	 to	quantify	phospho‐AMPK,	 total	AMPK,	phospho‐
ACC,	 total	 ACC,	 phospho‐RPS6,	 and	 total	 RPS6,	 at	 baseline	 and	
3 days after the final bout of PRT with metformin or placebo. In 
placebo,	 one	 phospho‐AMPK	outlier	 (>3	SD above the mean) was 
excluded	from	analyses.	Detailed	methods	are	given	in	Appendix	S5.
4.8 | Statistics
Statistical	 analyses	 were	 performed	 using	 SAS	 version	 9.4	 (SAS	
Institute). For all outcomes, statistical significance was set at 
p	<	.05,	using	two‐sided	tests.	All	continuous	measures	were	sum‐
marized with descriptive statistics, and distributions were tested 
for normality. Normally distributed measures are shown as mean 
and standard deviation (SD).	 Non‐normally	 distributed	measures	
are	 shown	 as	 median	 and	 IQR.	 All	 outcomes	 were	 analyzed	 as	
observed, and all analyses were performed on the analytic sam‐
ple (N	 =	 94).	 Paired	 t tests were used to examine changes with 
PRT.	Two‐sample	t tests were used to determine whether percent 
change in each outcome measure differed between the metformin 
and placebo groups; mean estimates with SD are presented. The 
chi‐square	 test	 was	 used	 to	 determine	 whether	 the	 distribution	
of sex or adverse events differed between groups. Pearson's cor‐
relation coefficient was used to assess relationships between 
measures	 of	muscle	 hypertrophy.	 Additional	 statistical	methods,	
including data quality assurance and power calculations, are given 
in	Appendix	S5.
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